SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (497)2/27/2003 6:01:30 PM
From: Icebrg  Read Replies (1) of 1022
 
Medarex's todo list for 2003.

At today's BIO presentation DD presented what he hopes MEDX will be able to achieve during the current year. Like last year the list isn't short. Let's hope that they succeed better in its implementation.

H1 2003
Expects to have data available at ASCO from phase II MDX-010 combination trial with GP 100 vaccine.

Expects to file:

IND for MDX-010 in breast cancer indication.

IND for MDX-010 in HIV indication

IND for MDX-067 which is cancer product developed in 50/50 partnership with OGS.

IND for MDX-214 which is an EGF-r targeted fusion protein.

Plus expects to enter into a number of corporate partnerships.

H2 2003.
Expects to initiate first phase III trial for MDX-010.

Expects to initiate multiple phase II trials for MDX-010.

Expects filing of IND for Colon Cancer product.

Expects at least 3 INDs from corporate cash and carry partners.

And to top it off. Even more corporate partnerships.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News